1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, et al:

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58: 826‑850, 2008. 2. Oka A, Mabuchi T, Ozawa A and Inoko H: Current under standing of human genetics and genetic analysis of psoriasis. J Dermatol 39: 231‑241, 2012. 3. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP and Fry L: A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 156: 258‑262, 2007. 4. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, et al: Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44: 1341‑1348, 2012. 5. Nestle FO, Kaplan DH and Barker J: Psoriasis. N Engl J Med 361: 496‑509, 2009. 6. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, et al: Sequence variants in the genes for the interleukin‑23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Human Genetics 122: 201‑206, 2007. 7. Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ and Tsai SF: Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol 156: 899‑905, 2007. 8. Magalhães RF, Biral AC, Pancoto JA, Donadi EA, Mendes CT Jr, Magna LA and Kraemer MH: Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)‑alpha ‑238 and ‑308 as genetic markers of suscep tibility to psoriasis and severity of the disease in a long‑term follow‑up Brazilian study. Int J Dermatol 49: 1133‑1140, 2010. 9. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, Westphal E, Guo SW, Christophers E, Voorhees JJ and Elder JT: Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome‑wide scan.

Hum Mol Genet 6: 1349‑1356, 1997. 10. Enlund F, Samuelsson L, Enerbäck C, Inerot A, Wahlström J, Yhr M, Torinsson A, Martinsson T and Swanbeck G: Analysis

of three suggested psoriasis susceptibility loci in a large Swedish set of families: Confirmation of linkage to chromosome 6p (HLA region) and to 17q, but not to 4q. Hum Hered 49: 2‑8, 1999.

11. Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY, Wei SC,

Chen SY, Xu SJ, Jin L, et al: Evidence for a major psoriasis

susceptibility locus at 6p21 (PSORS1) and a novel candidate region at 4q31 by genome‑wide scan in Chinese hans. J Invest Dermatol 119: 1361‑1366, 2002. 12. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C, et al: A genome‑wide association study identifies new psoriasis susceptibility loci and an interaction between HLA‑C and ERAP1. Nat Genet 42: 985‑990, 2010.

13. Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, Zhang FR, Zhang C, Du WH, Pu XM, et al: Psoriasis genome‑wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41: 205‑210, 2009.

14. Zhu KJ, Lv YM, Yin XY, Wang ZX, Sun LD, He SM, Cheng H, Hu DY, Zhang Z, Li Y, et al: Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PloS One 6: e23089, 2011.

15. Capon F, Bijlmakers MJ, Wolf N, Quaranta M, Huffmeier U,

Allen M, Timms K, Abkevich V, Gutin A, Smith R, et al: Identification of ZNF313/RNF114 as a novel psoriasis suscepti bility gene. Hum Mol Genet 17: 1938‑1945, 2008.

16. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, et al: A large‑scale genetic association study confirms IL12B and

leads to the identification of IL23R as psoriasis‑risk genes. Am J Hum Genet 80: 273‑290, 2007. 17. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, Sch reiber S, Kabelitz D, Lim H W, Voorhees JJ, et al: Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 128: 1653‑1661, 2008.

18. Chien AL, Elder JT and Ellis CN: Ustekinumab: A new option in psoriasis therapy. Drugs 69: 1141‑1152, 2009. 

19. Gandhi M, Alwawi E and Gordon KB: Anti‑p40 antibodies ustekinumab and briakinumab: blockade of interleukin‑12 and interleukin‑23 in the treatment of psoriasis. Seminars in cutaneous medicine and surgery 29: 48‑52, 2010. 

20. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus‑Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, et al: Comparison of ustekinumab and etanercept for moderate‑to‑severe psoriasis. N Engl J Med 362: 118‑128, 2010. 21. Kurzeja M, Rudnicka L and Olszewska M: New interleukin‑23 pathway inhibitors in dermatology: Ustekinumab, briakinumab and secukinumab. Am J Clin Dermatol 12: 113‑125, 2011. 22. Cornely R, Rentero C, Enrich C, Grewal T and Gaus K: Annexin A6 is an organizer of membrane microdomains to regulate receptor localization and signalling. IUBMB life 63: 1009‑1017, 2011.

23. Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH, Zhu QX,

Zhou HS, Ellinghaus E, Zhang FR, et al: Association analyses

identify six new psoriasis susceptibility loci in the Chinese popu lation. Nature Genet 42: 1005‑1009, 2010.